Academic Press Overcoming Drug Resistance in Gynecologic Cancers (Volume 17) (Cancer Sensitizing Agents for Chemotherapy, Volume 17)

Product Description Overcoming Drug Resistance in Gynecologic Cancers provides up-to-date information related to important gynecologic cancers and focuses on mechanisms of drug resistance, genetics, signaling, immunology, health disparities, nanotechnology, economic considerations and financial impacts. The book covers not only drug resistance but also important means to reverse resistance both in the laboratory and clinic. The book discusses topics such as lifestyle, nutrition and risk of gynecologic cancers, the financial impact of drug resistance, chemosensitizing agents and targeted therapies in cervical, endometrial and ovarian cancer, immunotherapy to overcome drug resistance, and genetic polymorphisms in gynecologic cancers. Additionally, it discusses ethnic and racial health disparity perspectives and future developments in chemosensitizing activities to reverse drug resistance in gynecologic cancers. It is a valuable resource for cancer researchers, oncologists, clinicians and other biomedical field members who are interested in new approaches to improve chemotherapy outcome in patients with gynecologic cancers. Review Provides up-to-date information on the basic mechanisms of drug resistance, health disparities, commercial impacts and new strategies From the Back Cover Overcoming Drug Resistance in Gynecologic Cancers provides up-to-date information related to important gynecologic cancers focusing on the mechanisms of drug resistance, genetics, signaling, immunology, health disparities, nanotechnology, and economic considerations/financial impact. It covers not only drug resistance but important means to reverse resistance both in the laboratory and clinic. The book discusses topics such as lifestyle, nutrition and risk of gynecologic cancers; the financial impact of drug resistance; chemosensitizing agents and targeted therapies in cervical, endometrial and ovarian cancer; immunotherapy to overcome drug resistance; and genetic polymorphisms in gynecologic cancers. Additionally, it discusses ethnic and racial health disparity perspectives and future developments in chemosensitizing activities to reverse drug resistance in gynecologic cancers. It is a valuable resource for cancer researchers, oncologists, clinicians and other biomedical field members who are interested in new approaches to improve chemotherapy outcome in patients with gynecologic cancers. About the Author Doctor Riyaz Basha is an Associate Professor & Vice Chair for Research in the Department of Pediatrics and Women’s Health, Texas College of Osteopathic Medicine, The University of North Texas Health Science Center (UNTHSC) at Fort Worth, TX, USA. He graduated with a PhD degree in 1999 from the Sri Venkateswara University, Tirupati, India, and received postdoctoral training at the University of Rhode Island, RI, USA. Before joining the UNTHSC in 2013, Dr. Basha was appointed as an Assistant Professor at the Cancer Research Institute of the MD Anderson Cancer Center at Orlando (currently named as UF Cancer Center), Orlando, FL, USA. Dr. Basha’s research is focused on improving cancer therapies in children, adolescents and adults. He has been working closely with physicians and researchers with emphasis on the translational principle of “bench to bedside. He has been investigating on drug resistance and novel strategies to improve the response of standard care/treatment, especially chemotherapy for various cancers including ovarian cancer. He has published his research findings in high impact factor journals such as Journal of Biological Chemistry, Cancer Letters, Cancer Medicine, Critical Reviews in Oncology/Hematology, and Gynecologic Oncology. Dr. Basha is a member of several scientific societies, including the Association of Biotechnology and Pharmacy (ABAP), American Association for Cancer Research, American Society of Clinical Oncology, and American Association for Clinical Chemistry (AACC) Academy. He